WO1999001175A1 - Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo - Google Patents

Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo Download PDF

Info

Publication number
WO1999001175A1
WO1999001175A1 PCT/EP1998/003976 EP9803976W WO9901175A1 WO 1999001175 A1 WO1999001175 A1 WO 1999001175A1 EP 9803976 W EP9803976 W EP 9803976W WO 9901175 A1 WO9901175 A1 WO 9901175A1
Authority
WO
WIPO (PCT)
Prior art keywords
pulses
electrode
tissue
volts
electrotransfer
Prior art date
Application number
PCT/EP1998/003976
Other languages
English (en)
French (fr)
Inventor
Michel Bureau
Lluis Mir
Daniel Scherman
Bertrand Schwartz
Original Assignee
Rhone-Poulenc Rorer S.A.
Institut Gustave Roussy
Centre National De La Recherche Scientifique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9708232A external-priority patent/FR2765241B1/fr
Priority claimed from FR9708233A external-priority patent/FR2765242B1/fr
Application filed by Rhone-Poulenc Rorer S.A., Institut Gustave Roussy, Centre National De La Recherche Scientifique filed Critical Rhone-Poulenc Rorer S.A.
Priority to CA002295029A priority Critical patent/CA2295029A1/en
Priority to BR9810500-0A priority patent/BR9810500A/pt
Priority to IL13370998A priority patent/IL133709A0/xx
Priority to AU87307/98A priority patent/AU8730798A/en
Priority to EP98938676A priority patent/EP0993318A1/en
Priority to JP50807599A priority patent/JP2002515816A/ja
Publication of WO1999001175A1 publication Critical patent/WO1999001175A1/en
Priority to NO996540A priority patent/NO996540L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PCT/EP1998/003976 1997-06-30 1998-06-30 Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo WO1999001175A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002295029A CA2295029A1 (en) 1997-06-30 1998-06-30 Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo
BR9810500-0A BR9810500A (pt) 1997-06-30 1998-06-30 Sistema e aparelho para a transferência de ácido nucléico in vivo para o interior de células de organismos eucarióticos pluricelulares
IL13370998A IL133709A0 (en) 1997-06-30 1998-06-30 Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo
AU87307/98A AU8730798A (en) 1997-06-30 1998-06-30 Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo
EP98938676A EP0993318A1 (en) 1997-06-30 1998-06-30 Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo
JP50807599A JP2002515816A (ja) 1997-06-30 1998-06-30 ｉｎ ｖｉｖｏ組織に核酸ベクターを最適に電気導入する装置
NO996540A NO996540L (no) 1997-06-30 1999-12-29 Innretning for optimalisert elektrooverfoering av nukleinsyrevektorer til vev in vivo

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
FR97/08233 1997-06-30
FR9708232A FR2765241B1 (fr) 1997-06-30 1997-06-30 Amelioration du transfert d'acide nucleique dans les cellules d'organismes eucaryotes pluricellulaires et combinaison permettant la mise en oeuvre du procede
FR97/08232 1997-06-30
FR9708233A FR2765242B1 (fr) 1997-06-30 1997-06-30 Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
US6748797P 1997-12-01 1997-12-01
US6748897P 1997-12-01 1997-12-01
US60/067,488 1997-12-01
US60/067,487 1997-12-01
US8385898P 1998-05-01 1998-05-01
US60/083,858 1998-05-01

Publications (1)

Publication Number Publication Date
WO1999001175A1 true WO1999001175A1 (en) 1999-01-14

Family

ID=27515625

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/003976 WO1999001175A1 (en) 1997-06-30 1998-06-30 Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo

Country Status (11)

Country Link
EP (1) EP0993318A1 (ko)
JP (1) JP2002515816A (ko)
KR (1) KR20010014298A (ko)
CN (1) CN1261812A (ko)
AU (1) AU8730798A (ko)
BR (1) BR9810500A (ko)
CA (1) CA2295029A1 (ko)
IL (1) IL133709A0 (ko)
NO (1) NO996540L (ko)
PL (1) PL337617A1 (ko)
WO (1) WO1999001175A1 (ko)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068131A1 (en) 2000-03-13 2001-09-20 Cornell Research Foundation, Inc. Blocking leukocyte emigration and inflammation by interfering with cd99/hec2
EP1148885A1 (en) * 1999-02-08 2001-10-31 Chiron Corporation Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo
WO2001085202A2 (en) * 1997-04-03 2001-11-15 Electrofect As Electroporation for introduction of molecules into cells
WO2002070665A2 (en) 2001-03-02 2002-09-12 The Rockefeller University Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen
WO2003075978A2 (en) 2002-03-07 2003-09-18 Merck & Co., Inc. Clinical syringe with electrical stimulation aspects
US6723315B1 (en) 1996-09-13 2004-04-20 Aventis Pharma S.A. Method for treating amyotrophic lateral sclerosis
EP1409076A2 (en) * 2001-06-07 2004-04-21 Ramot at Tel Aviv University Ltd. Method and apparatus for treating tumors using low strength electric fields
US6928318B2 (en) 2000-05-22 2005-08-09 Merck & Co., Inc. System and method for assessing the performance of a pharmaceutical agent delivery system
EP1759714A1 (en) * 2005-09-02 2007-03-07 Bioalliance Pharma Electrotransfer of nucleic acid into tissue cells
US7416726B2 (en) 2000-04-13 2008-08-26 The Rockefeller University Enhancement of antibody-mediated immune responses
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
EP2316922A1 (en) 2002-05-24 2011-05-04 Schering Corporation Neutralizing human anti-IGFR antibody
EP2332961A2 (en) 2001-10-11 2011-06-15 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP2402359A1 (en) 2000-12-28 2012-01-04 Wyeth LLC Recombinant protective protein from streptococcus pneumoniae
US8093043B2 (en) 2008-06-04 2012-01-10 New York University β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis
EP2530090A2 (en) 2006-10-19 2012-12-05 CSL Limited Anti-IL-13R alpha 1 antibodies and their uses thereof
US8563001B2 (en) 2008-11-05 2013-10-22 Regents Of The University Of Minnesota Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease
US8574597B2 (en) 2006-12-22 2013-11-05 Wyeth Llc Immunogenic compositions for the prevention and treatment of meningococcal disease
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
EP2829551A1 (en) 2006-10-19 2015-01-28 CSL Limited High affinity antibody antagonists of interleukin-13 receptor alpha 1
US8986710B2 (en) 2012-03-09 2015-03-24 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US9556240B2 (en) 2010-08-23 2017-01-31 Wyeth Llc Stable formulations of Neisseria meningitidis rLP2086 antigens
US9757443B2 (en) 2010-09-10 2017-09-12 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
US9822150B2 (en) 2013-09-08 2017-11-21 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10196429B2 (en) 2012-03-09 2019-02-05 Pfizer Inc. Neisseria meningitidis composition and methods thereof
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3804809B1 (en) * 2005-10-03 2023-12-27 Novocure GmbH Optimizing characteristics of an electric field to increase the field's effect on proliferating cells
JP4961137B2 (ja) * 2005-12-14 2012-06-27 久光製薬株式会社 イオントフォレーシス用デバイス
US8246176B2 (en) 2007-03-06 2012-08-21 Sanyo Electric Co., Ltd. Projection display device having an operation section for displacing a lens
CN102124102B (zh) * 2008-07-18 2013-12-18 麦克赛特股份有限公司 优化电穿孔的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006129A2 (en) * 1993-08-20 1995-03-02 Therexsys Limited Transfection process
WO1996014836A1 (en) * 1994-11-14 1996-05-23 Incell Method and apparatus for gene therapy
WO1997007826A1 (en) * 1995-08-29 1997-03-06 Cbr Laboratories, Inc. In vivo electroporation of cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006129A2 (en) * 1993-08-20 1995-03-02 Therexsys Limited Transfection process
WO1996014836A1 (en) * 1994-11-14 1996-05-23 Incell Method and apparatus for gene therapy
WO1997007826A1 (en) * 1995-08-29 1997-03-06 Cbr Laboratories, Inc. In vivo electroporation of cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HELLER ET AL: "IN VIVO GENE ELECTROINJECTION AND EXPRESSION IN RAT LIVER", FEBS LETTERS, vol. 389, 1996, pages 225 - 228, XP002058383 *
NISHI ET AL: "HIGH-EFFICIENCY IN VIVO GENE TRANSFER USING INTRAARTERIAL PLASMID DNA INJECTION FOLLOWING IN VIVO ELECTROPORATION", CANCER RESEARCH, vol. 56, 1996, pages 1050 - 1055, XP002058384 *

Cited By (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723315B1 (en) 1996-09-13 2004-04-20 Aventis Pharma S.A. Method for treating amyotrophic lateral sclerosis
WO2001085202A2 (en) * 1997-04-03 2001-11-15 Electrofect As Electroporation for introduction of molecules into cells
WO2001085202A3 (en) * 1997-04-03 2002-03-28 Electrofect As Electroporation for introduction of molecules into cells
US7931640B2 (en) 1997-04-03 2011-04-26 Inovio As Method for muscle delivery of drugs, nucleic acids and other compounds
EP1148885A1 (en) * 1999-02-08 2001-10-31 Chiron Corporation Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo
EP1148885A4 (en) * 1999-02-08 2002-05-08 Chiron Corp ELECTRICALLY INDUCED INCREASE IN IMMUNITY AND EFFECTIVENESS OF IN VIVO DNA VACCINES
WO2001068131A1 (en) 2000-03-13 2001-09-20 Cornell Research Foundation, Inc. Blocking leukocyte emigration and inflammation by interfering with cd99/hec2
EP2264072A1 (en) 2000-04-13 2010-12-22 The Rockefeller University Enhancement of antibody-mediated cytotoxicity.
US7416726B2 (en) 2000-04-13 2008-08-26 The Rockefeller University Enhancement of antibody-mediated immune responses
US6928318B2 (en) 2000-05-22 2005-08-09 Merck & Co., Inc. System and method for assessing the performance of a pharmaceutical agent delivery system
EP2402359A1 (en) 2000-12-28 2012-01-04 Wyeth LLC Recombinant protective protein from streptococcus pneumoniae
WO2002070665A2 (en) 2001-03-02 2002-09-12 The Rockefeller University Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen
EP1409076A4 (en) * 2001-06-07 2009-04-08 Univ Ramot METHOD AND DEVICE FOR TREATING TUMORS USING ELECTRIC FIELDS WITH LOW POWER
EP1409076A2 (en) * 2001-06-07 2004-04-21 Ramot at Tel Aviv University Ltd. Method and apparatus for treating tumors using low strength electric fields
EP2332961A2 (en) 2001-10-11 2011-06-15 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP2351767A2 (en) 2001-10-11 2011-08-03 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
US9757444B2 (en) 2001-10-11 2017-09-12 Wyeth Holdings Llc Immunogenic compositions for the prevention and treatment of meningococcal disease
US10300122B2 (en) 2001-10-11 2019-05-28 Wyeth Holdings Llc Immunogenic compositions for the prevention and treatment of meningococcal disease
US8563006B2 (en) 2001-10-11 2013-10-22 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US9132182B2 (en) 2001-10-11 2015-09-15 Wyeth Holdings Llc Immunogenic compositions for the prevention and treatment of meningococcal disease
US9107873B2 (en) 2001-10-11 2015-08-18 Wyeth Holdings Llc Immunogenic compositions for the prevention and treatment of meningococcal disease
EP2341063A2 (en) 2001-10-11 2011-07-06 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP2341062A2 (en) 2001-10-11 2011-07-06 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP2343308A2 (en) 2001-10-11 2011-07-13 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP2348034A2 (en) 2001-10-11 2011-07-27 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP2348035A2 (en) 2001-10-11 2011-07-27 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP2348036A2 (en) 2001-10-11 2011-07-27 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
US8563007B1 (en) 2001-10-11 2013-10-22 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
EP2366707A1 (en) 2001-10-11 2011-09-21 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP2371838A1 (en) 2001-10-11 2011-10-05 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP2371836A1 (en) 2001-10-11 2011-10-05 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
EP2371837A1 (en) 2001-10-11 2011-10-05 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
US11116829B2 (en) 2001-10-11 2021-09-14 Wyeth Holdings Llc Immunogenic compositions for the prevention and treatment of meningococcal disease
EP3199539A1 (en) 2001-10-11 2017-08-02 Wyeth Holdings LLC Novel immunogenic compositions for the prevention and treatment of meningococcal disease
US8101194B2 (en) 2001-10-11 2012-01-24 Wyeth Llc Immunogenic compositions for the prevention and treatment of meningococcal disease
US9623101B2 (en) 2001-10-11 2017-04-18 Wyeth Holdings Llc Immunogenic compositions for the prevention and treatment of meningococcal disease
US9168293B2 (en) 2001-10-11 2015-10-27 Wyeth Holdings Llc Immunogenic compositions for the prevention and treatment of meningococcal disease
WO2003075978A2 (en) 2002-03-07 2003-09-18 Merck & Co., Inc. Clinical syringe with electrical stimulation aspects
EP2316921A1 (en) 2002-05-24 2011-05-04 Schering Corporation Neutralizing human anti-IGFR antibody
EP2316922A1 (en) 2002-05-24 2011-05-04 Schering Corporation Neutralizing human anti-IGFR antibody
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US8227435B2 (en) 2005-09-02 2012-07-24 Bioalliance Pharma Electrotransfer of nucleic acid into tissue cells
WO2007026236A2 (en) * 2005-09-02 2007-03-08 Bioalliance Pharma Electrotransfer of nucleic acid into tissue cells
WO2007026236A3 (en) * 2005-09-02 2007-05-03 Bioalliance Pharma Electrotransfer of nucleic acid into tissue cells
EP1759714A1 (en) * 2005-09-02 2007-03-07 Bioalliance Pharma Electrotransfer of nucleic acid into tissue cells
AU2006286306B2 (en) * 2005-09-02 2012-04-19 Bioalliance Pharma Electrotransfer of nucleic acid into tissue cells
EP2530090A2 (en) 2006-10-19 2012-12-05 CSL Limited Anti-IL-13R alpha 1 antibodies and their uses thereof
EP2829551A1 (en) 2006-10-19 2015-01-28 CSL Limited High affinity antibody antagonists of interleukin-13 receptor alpha 1
US8574597B2 (en) 2006-12-22 2013-11-05 Wyeth Llc Immunogenic compositions for the prevention and treatment of meningococcal disease
US8093043B2 (en) 2008-06-04 2012-01-10 New York University β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis
US8563001B2 (en) 2008-11-05 2013-10-22 Regents Of The University Of Minnesota Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease
US9127050B2 (en) 2008-11-05 2015-09-08 Regents Of The University Of Minnesota Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease
US9556240B2 (en) 2010-08-23 2017-01-31 Wyeth Llc Stable formulations of Neisseria meningitidis rLP2086 antigens
US11077180B2 (en) 2010-09-10 2021-08-03 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
US10512681B2 (en) 2010-09-10 2019-12-24 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
US9757443B2 (en) 2010-09-10 2017-09-12 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
US10550159B2 (en) 2012-03-09 2020-02-04 Pfizer Inc. Neisseria meningitidis composition and methods thereof
US10829521B2 (en) 2012-03-09 2020-11-10 Pfizer Inc. Neisseria meningitidis composition and methods thereof
US11472850B2 (en) 2012-03-09 2022-10-18 Pfizer Inc. Neisseria meningitidis composition and methods thereof
US10196429B2 (en) 2012-03-09 2019-02-05 Pfizer Inc. Neisseria meningitidis composition and methods thereof
US8986710B2 (en) 2012-03-09 2015-03-24 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US9724402B2 (en) 2012-03-09 2017-08-08 Pfizer Inc. Neisseria meningitidis composition and methods thereof
US9561269B2 (en) 2012-03-09 2017-02-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
US9822150B2 (en) 2013-09-08 2017-11-21 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10899802B2 (en) 2013-09-08 2021-01-26 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US11680087B2 (en) 2013-09-08 2023-06-20 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10813989B2 (en) 2017-01-31 2020-10-27 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10543267B2 (en) 2017-01-31 2020-01-28 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US11730800B2 (en) 2017-01-31 2023-08-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Also Published As

Publication number Publication date
CN1261812A (zh) 2000-08-02
IL133709A0 (en) 2001-04-30
EP0993318A1 (en) 2000-04-19
JP2002515816A (ja) 2002-05-28
NO996540L (no) 2000-02-03
BR9810500A (pt) 2000-09-05
PL337617A1 (en) 2000-08-28
KR20010014298A (ko) 2001-02-26
CA2295029A1 (en) 1999-01-14
NO996540D0 (no) 1999-12-29
AU8730798A (en) 1999-01-25

Similar Documents

Publication Publication Date Title
EP0993318A1 (en) Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo
US6939862B2 (en) Method for transferring nucleic acid into striated muscles
JP4664450B2 (ja) 多細胞化真核生物細胞に核酸を導入する改良法およびその組合せ
US7054685B2 (en) Method and apparatus for reducing electroporation-mediated muscle reaction and pain response
Vicat et al. Brief report: muscle transfection by electroporation with high-voltage and short-pulse currents provides high-level and long-lasting gene expression
Heller et al. Electrically mediated delivery of plasmid DNA to the skin, using a multielectrode array
EP1171189B1 (en) Apparatus for reducing electroporation-mediated muscle reaction and pain response
WO1999036563A1 (en) Electrically mediated cellular expression
MXPA99011527A (en) Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo
CZ475699A3 (cs) Systém a zařízení pro in vivo přenos nukleových kyselin do tkání
MXPA99011444A (es) Metodo mejorado de transferencia de acidos nucleicos enmusculo estraido y combinaciones que permienn el uso del procedimiento
JP2005524389A (ja) 宿主組織内への核酸分子の電気的遺伝子導入の増強
AU4439102A (en) Improved method for transferring nucleic acid into the striped muscle and combination therefor
AU4576202A (en) Improvement in the transfer of nucleic acid into the cells of pluricellular eukaryotic organisms and combination allowing the method to be carried out

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 133709

Country of ref document: IL

Ref document number: 98806793.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE GW HU ID IL IS JP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/011527

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 87307/98

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2295029

Country of ref document: CA

Ref document number: 2295029

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998938676

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV1999-4756

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1019997012430

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 09446580

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998938676

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1999-4756

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019997012430

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1998938676

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998938676

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019997012430

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV1999-4756

Country of ref document: CZ